There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.

Mesenchymal stem cells have encouraging early data in ARDS, but the stem cell industry’s shady reputation complicates perception – and trial enrollment.

Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.

News and views from day one of  BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change.